102 results on '"Regueiro, Miguel D."'
Search Results
2. White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory Bowel Disease
3. Pediatric autoimmune enteropathy: an entity frequently associated with immunodeficiency disorders
4. Tu1852 DIVORCE AND WIDOWHOOD NEGATIVELY IMPACT INFLAMMATORY BOWEL DISEASE - A NATIONWIDE COHORT ANALYSIS
5. Su1797 ETRASIMOD SHOWS LOW RISK OF ADVERSE EVENTS FOLLOWING CONCOMITANT USE WITH OPIOIDS OR ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
6. Su1791 DURABILITY OF RESPONSE IN DELAYED RESPONDERS TO OZANIMOD IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGICS: 3-YEAR UPDATE FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
7. 763 RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
8. Sa1777 IBD PATIENTS CONCOMITANTLY TREATED WITH GLP1 AGONISTS HAD FEWER HOSPITALIZATIONS AND DISEASE RELATED COMPLICATIONS: A US COHORT PROPENSITY-MATCHED STUDY
9. Sa1754 PARADOXICAL RISK OF RHEUMATOID ARTHRITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS EXPOSED TO TUMOR NECROSIS FACTOR INHIBITORS: A PROPENSITY MATCHED MULTI-NETWORK STUDY
10. Sa1743 BIOLOGICS AND ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED MAJOR ADVERSE CARDIOVASCULAR EVENTS OR VENOUS THROMBOEMBOLISM IN OLDER IBD PATIENTS
11. Sa1011 PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHO SPEAK A NON-ENGLISH PRIMARY LANGUAGE HAVE HIGHER RATES OF UNPLANNED CARE AND LOWER USE OF ADVANCED THERAPIES: A POPULATION-BASED MULTI-NETWORK ANALYSIS
12. Tu1887 EFFICACY AND SAFETY OF SEMAGLUTIDE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND OBESITY
13. Tu1883 CHARACTERISTICS AND PREDICTORS OF LONG-TERM REMITTERS AFTER ILEOCOLONIC RESECTION FOR CROHN'S DISEASE
14. 720 ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED CANCER RATES IN IBD PATIENTS
15. 246 COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN'S DISEASE.
16. Mo1841 RATES OF ESCALATION TO ADVANCED THERAPY IN PATIENTS WITH ULCERATIVE PROCTITIS AT SIX MONTHS, ONE YEAR, AND TWO YEARS POST DIAGNOSIS
17. Mo1353 MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) AND VENOUS TROMBOEMBOLISM (VTE) ARE NOT INCREASED IN MICROSCOPIC COLITIS: A PROPENSITY MATCHED MULTI-NETWORK STUDY
18. Su1853 INCREASED PSYCHIATRIC COMORBIDITIES AND RISK OF SUICIDE IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE 6-12 MONTHS AFTER INITIAL DIAGNOSIS: A MULTI-NETWORK PROPENSITY-MATCHED COHORT STUDY
19. 1095 EXHALED BREATH ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IS ASSOCIATED WITH LUMINAL DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS
20. 116 - Management of Inflammatory Bowel Diseases
21. 237 DEVELOPMENT AND VALIDATION OF A RISK CALCULATOR FOR MORTALITY AMONG GENERAL SURGERY PATIENTS AT THE TIME OF INTER-HOSPITAL TRANSFER
22. Tu1773 POSTOPERATIVE PROPHYLAXIS WITH NEW COMPARED TO RECYCLED BIOLOGIC CLASSES HAVE SIMILAR RATES OF BUT EARLIER TIME TO POSTOPERATIVE RECURRENCE IN BIOLOGIC EXPERIENCED CROHN'S DISEASE PATIENTS UNDERGOING ILEOCOLONIC RESECTION
23. Tu1743 ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF INFECTION RATES FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 CLINICAL TRIALS
24. Tu1742 ENDOSCOPIC, HISTOLOGIC, AND COMBINED OUTCOMES WITH REINITIATION OF OZANIMOD AFTER TEMPORARY DISCONTINUATION: 2-YEAR INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
25. Tu1716 UPADACITINIB THERAPY REDUCES CROHN'S DISEASE SYMPTOMS WITHIN THE FIRST WEEK OF INDUCTION THERAPY
26. Mo1767 USING FECAL CALPROTECTIN TO PREDICT ENDOSCOPIC RECURRENCE IN POST-OPERATIVE CROHN'S DISEASE
27. Mo1774 RISK OF EXTRA-INTESTINAL SOLID ORGAN MALIGNANCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A US-BASED PROPENSITY MATCHED COHORT STUDY
28. Mo1745 HISTOLOGIC ACTIVITY DESPITE ENDOSCOPIC REMISSION PREDICTS CROHN'S DISEASE RECURRENCE FOLLOWING ILEOCOLONIC RESECTION
29. Mo1039 CREATION OF A SUBSPECIALTY LEARNING COMMUNITY FOR ADVANCED INFLAMMATORY BOWEL DISEASE FELLOWS ANCHORED IN COMPETENCY BASED EDUCATION: THE MILESTONE INITIATIVE
30. Su1778 LOW RATES OF PNEUMOCOCCAL VACCINATION ADMINISTRATION IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTICENTER POPULATION-BASED STUDY
31. Su1711 EFFICACY AND SAFETY OF TOFACITINIB AFTER FAILURE OF ANTI-TNF AGENT IN PATIENTS WITH ULCERATIVE COLITIS: A US-BASED PROPENSITY MATCHED COHORT STUDY
32. Su1704 CHARACTERIZATION OF CARDIAC CONDUCTION ABNORMALITIES REPORTED IN THE PHASE 3 ELEVATE PROGRAM
33. Su1121 BIOLOGIC THERAPY PREVENTS COVID RELATED COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
34. Sa1831 SIMILAR POSTOPERATIVE RECURRENCE RISK AMONGST INTERNAL PENETRATING CROHN'S DISEASE PHENOTYPES
35. Sa1781 THE OUTCOMES OF IBD IN PATIENTS WHO RECEIVED TOCILIZUMAB DURING COVID-19 PANDEMIC: A U.S. COHORT PROPENSITY SCORE MATCHED STUDY
36. Sa1779 THE EPIDEMIOLOGY AND CHARACTERISTICS OF DE NOVO IBD AFTER SOLID ORGAN OR HEMATOPOIETIC STEM CELL TRANSPLANT BETWEEN 2011-2021: A LARGE POPOULATION-BASED STUDY
37. Sa1780 IMPACT OF BARIATRIC SURGERY ON THE OUTCOMES OF INFLAMMATORY BOWEL DISEASE: A U.S. COHORT PROPENSITYMATCHED STUDY
38. 963 BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS
39. 948 ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 2.5 YEARS OF POOLED SAFETY DATA FROM GLOBAL CLINICAL TRIALS
40. 201 SESSILE SERRATED POLYP DETECTION RATE IN ASYMPTOMATIC AVERAGE RISK INDIVIDUALS WITH POSITIVE FECAL IMMUNOCHEMICAL AND MULTITARGET STOOL DNA TEST: A SYSTEMATIC REVIEW AND META-ANALYSIS
41. 15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS
42. Sa673 TWISTED POUCH SYNDROME - A DIFFICULT TO DIAGNOSE MECHANICAL COMPLICATION OF ILEAL POUCH-ANAL ANASTOMOSIS: OUTCOMES AFTER REDO POUCH PROCEDURES
43. Su470 IMPACT OF BIOLOGICS ON THE PREVALENCE OF MIGRAINE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION-BASED STUDY
44. Su461 SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB
45. Su455 SIMILAR RATES OF POSTOPERATIVE OBJECTIVE RECURRENCE IN ADULT CROHN'S DISEASE PATIENTS ON DIFFERENT POSTOPERATIVE BIOLOGIC THERAPIES
46. Sa580 REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH CROHN'S DISEASE
47. Sa572 RISK OF DEPRESSION AND ANXIETY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CO-MORBID RHEUMATOID ARTHRITIS
48. Sa553 UTILIZATION OF BIOLOGIC MEDICATIONS AND IMMUNOMODULATORS AMONG PATIENTS WITH HEART FAILURE AND CROHN'S DISEASE IN THE UNITED STATES BETWEEN 2015 AND 2020: A POPULATION-BASED STUDY
49. Sa552 UTILIZATION OF BIOLOGIC MEDICATIONS AND IMMUNOMODULATORS AMONG PATIENTS WITH HEART FAILURE AND ULCERATIVE COLITIS IN THE UNITED STATES BETWEEN 2015 AND 2020: A POPULATION-BASED STUDY
50. Sa462 ACCURACY OF IMAGING IN DETECTING POSTOPERATIVE CROHN'S DISEASE RECURRENCE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.